Looking for what’s next in prostate cancer?

Tomorrow’s treatments are developed in today’s clinical trials.

Doctors and scientists have significantly advanced treatments for men with prostate cancer over the last 10 years, but there is more work to be done. Pfizer is conducting a series of clinical trials to find out if a study medicine (mevrometostat) is safe and works to slow down or stop the growth of metastatic prostate cancer.

We encourage you to learn more and consider enrolling in one of our ongoing clinical trials. Your participation can make a difference for yourself and for other people diagnosed with prostate cancer.

Participating in a clinical trial is an important and personal decision. As you consider your next steps, thank you for taking time to learn more about the MEVPRO metastatic prostate cancer clinical trials.

About the study medicine

The MEVPRO clinical trials are evaluating the safety and effectiveness of a study medicine in treating metastatic prostate cancer.

Study medicine (mevrometostat):

Prostate cancer cells need hormones (such as testosterone) to grow and divide. Using ‘hormone therapy’ to reduce hormones or block their effects is one way of treating prostate cancer.

EZH2 is a gene that directs the production of proteins which control the growing, dividing or repairing of cells. In some people, the EZH2 gene may become abnormal or make too much of the proteins, which can cause prostate cancer cells to grow, and the cancer can progress.

The study medicine is thought to work by blocking the abnormal EZH2 activity in cells, which may help prevent or delay hormone therapy resistance and cancer growth and progression.

The study medicine (mevrometostat) is taken as tablets by mouth twice-a-day and is not yet approved for treating prostate cancer.

For more information about the study medicine, please watch the short video below.

Participating in these trials

Each clinical trial in the MEVPRO program will have its own unique requirements for who may participate. If you have developed resistance to available treatments and your cancer has spread to other parts of the body, the MEVPRO clinical trials may be an option for you. The requirements may include your stage of prostate cancer and any previous treatments you may have received.

You can talk with the study doctor to find out which clinical trial may be right for you.

To learn more about the requirements for a clinical trial that is enrolling, visit the webpages via the links below. You may also speak with the study team, your oncologist, and/or another health care provider. Only the study team (at a study site) can determine if you qualify to enrol in a clinical trial.

Condition

The disease, disorder, syndrome, illness, or injury that is being studied.

Metastatic prostate cancer

Age

The age a person must be to participate in the studies in this program.

18+ years

Sex

The sex of people who may participate in the studies in this program. Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.

Male

Enrolling MEVPRO metastatic prostate cancer clinical trials

All of the below studies are for people with metastatic prostate cancer.

MEVPRO-1

For: Adults with metastatic castrate-resistant prostate cancer who were previously treated with abiraterone acetate (Zytiga®) for at least 12 weeks

Phase: 3

Study treatment: Participants will receive either:

the study medicine (mevrometostat) in combination with
standard-of-care treatment Standard-of-care treatments are established treatments that are widely accepted by medical professionals and may vary depending on where a patient lives.
(enzalutamide)

standard-of-care treatment alone (enzalutamide or docetaxel)

MEVPRO-2

For: Adults with metastatic castrate-resistant prostate cancer who have not tried hormonal therapy or chemotherapy (for castrate-resistant cancer)

Phase: 3

Study treatment: Participants will receive either:

the study medicine (mevrometostat) in combination with
standard-of-care treatment Standard-of-care treatments are established treatments that are widely accepted by medical professionals and may vary depending on where a patient lives.
(enzalutamide)

placebo A placebo does not have any medicine in it but looks just like the medicine being studied.
in combination with standard-of-care treatment (enzalutamide)

The importance of representation

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime. Many factors, including genetics, race, and ethnicity can impact how people respond to a medicine. That is why it is so important that clinical trials include people of all backgrounds. The greater the diversity among clinical trial participants, the more we can learn about potential medicines, including how they work for different people.

When you take part in a clinical trial, you’re helping to represent people of similar backgrounds or ancestry and all people who are affected by prostate cancer. Your participation in one of the MEVPRO clinical trials may help advance treatments for people across the globe.

About prostate cancer

Prostate cancer is one of the most common types of cancer. Metastatic prostate cancer is when it has spread from the prostate to other parts of the body. Prostate cancer cells need hormones (such as testosterone) to grow and divide. Using ‘hormone therapy’ to reduce hormones or block their effects is one way of treating prostate cancer.

Unfortunately, prostate cancer can often become resistant to hormone therapy and continue to progress and spread to other parts of the body.

Metastatic castrate-sensitive prostate cancer (mCSPC) is advanced prostate cancer which can no longer be treated with local therapy (surgery or radiation) alone. Men who have not yet tried hormone therapy or their cancer is still responding to hormone therapy may have mCSPC.

Metastatic castrate-resistant prostate cancer (CRPC) is advanced prostate cancer that has progressed (worsened) and is no longer responding to hormone therapy.

Metastatic prostate cancer is still incurable which leads us to build on the previous advancements in the treatment of prostate cancer. If your prostate cancer has progressed, one of these clinical trials may be right for you.

How clinical trials work

Steps to join a clinical trial

Protecting your safety & privacy

FAQs